BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Hematology

...anemia. Pieris AG's PRS-080, an anticalin targeting hepcidin, is also in preclinical development for anemia. Ferrumax Pharmaceuticals Inc....
...doi:10.1038/scibx.2011.797 Published online July 21, 2011 HFE2-Fc patented by Massachusetts General Hospital; exclusively licensed to Ferrumax...
Items per page:
1 - 1 of 1
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Hematology

...anemia. Pieris AG's PRS-080, an anticalin targeting hepcidin, is also in preclinical development for anemia. Ferrumax Pharmaceuticals Inc....
...doi:10.1038/scibx.2011.797 Published online July 21, 2011 HFE2-Fc patented by Massachusetts General Hospital; exclusively licensed to Ferrumax...
Items per page:
1 - 1 of 1